

Department of Planning and Budget

2015 Fiscal Impact Statement

1. Bill Number: HB 2050

House of Origin	<input checked="" type="checkbox"/> Introduced	<input type="checkbox"/> Substitute	<input type="checkbox"/> Engrossed
Second House	<input type="checkbox"/> In Committee	<input type="checkbox"/> Substitute	<input type="checkbox"/> Enrolled

2. Patron: Sickles

3. Committee: Committee Referral Pending

4. Title: Expanded access to investigational drugs, biological products, and devices.

5. Summary: Expanded access to investigational drugs, biological products, and devices. Provides that a manufacturer of an investigational drug, biological product, or device may make such drug, product, or device available to a person who has a terminal illness when (i) the person has a terminal condition; (ii) the person has, in consultation with his physician, considered all other treatment options currently approved by the U.S. Food and Drug Administration; (iii) the person's physician has recommended treatment with an investigational drug, biological product, or device; and (iv) the person has provided written informed consent. The bill provides that a manufacturer that provides such drug, product, or device may provide it free of charge or may require the person to pay costs associated with its manufacture.

6. Budget Amendment Necessary: No.

7. No Fiscal Impact.

8. Fiscal Implications: This bill would not have a fiscal impact on the Commonwealth. The Department of Health Professions has stated that this bill would not impact operations.

9. Specific Agency or Political Subdivisions Affected: Department of Health Professions.

10. Technical Amendment Necessary: No.

11. Other Comments: This bill is similar to HB1750, SB732, SB1149, and SB1222.